Actionnariat et activité des initiés pour Fate Therapeutics, Inc. (FATE): transactions des initiés, déclarations de trading du Sénat et de la Chambre américaine et actions en circulation. Suivez comment dirigeants et politiciens négocient le titre.
Prix
| Prix | $2.44 |
| Capitalisation | $284M |
| Bourse | NASDAQ |
| Pays | US |
Bilan (10 ans)
| Année | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Trésorerie | $88.6M | $89.0M | $190.5M | $99.8M | $167.3M | $133.6M | $61.3M | $41.9M | $36.1M | $46.6M |
| Placements à Court Terme | $3.5M | $12.0M | $10.5M | $121.6M | $315.6M | $482.3M | $374.9M | $273.3M | $243.0M | $157.0M |
| Créances | 0 | 0 | $500000 | 0 | $5.5M | $8.7M | $38.5M | $1.8M | $3.5M | $916000 |
| Stocks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Actifs Courants | $93.3M | $102.6M | $205.2M | $227.1M | $494.3M | $633.4M | $502.1M | $331.5M | $291.9M | $208.7M |
| Immobilisations Corporelles | $1.6M | $2.5M | $5.1M | $22.8M | $99.4M | $162.2M | $66.1M | $158.5M | $110.9M | $98.5M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Actifs Incorporels | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Actifs Totaux | $95.0M | $105.3M | $213.0M | $302.3M | $622.5M | $921.5M | $705.6M | $506.2M | $440.7M | $318.9M |
| Dettes Fournisseurs | $934000 | $1.7M | $4.2M | $5.8M | $6.3M | $8.6M | $8.3M | $4.7M | $9.4M | $2.7M |
| Dette à Court Terme | $8.2M | 0 | $2.4M | 0 | $3.4M | 0 | 0 | $6.2M | 0 | 0 |
| Passifs Courants | $15.2M | $11.0M | $27.3M | $27.8M | $85.6M | $81.3M | $114.1M | $39.1M | $38.5M | $36.1M |
| Dette à Long Terme | $2.5M | $14.8M | $12.4M | 0 | 0 | 0 | 0 | 0 | 0 | $73.3M |
| Passifs Totaux | $21.9M | $28.1M | $52.6M | $57.5M | $238.0M | $242.6M | $221.6M | $137.8M | $122.0M | $111.8M |
| Réserves | -$175.8M | -$218.8M | -$285.4M | -$383.5M | -$556.9M | -$769.1M | -$1.05B | -$1.21B | -$1.40B | -$1.53B |
| Capitaux Propres | $73.2M | $77.2M | $160.5M | $244.8M | $384.4M | $678.8M | $483.9M | $368.4M | $318.7M | $207.2M |
| Dette Totale | $10.7M | $14.8M | $14.9M | $26.9M | $97.3M | $114.8M | $109.3M | $103.5M | $85.3M | $77.8M |
| Dette Nette | -$81.4M | -$86.1M | -$186.1M | -$194.5M | -$385.6M | -$501.1M | -$326.9M | -$211.6M | -$193.8M | -$125.8M |
| Fonds de Roulement | $78.1M | $91.5M | $177.9M | $199.3M | $408.8M | $552.1M | $388.0M | $292.4M | $253.4M | $172.6M |
Santé financière
| Dette / Capitaux propres | 0.49 |
| Ratio de liquidité | 4.85 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -6.97 |
Rentabilité
| Rentabilité des capitaux propres | -65.08% |
| Rentabilité du capital investi | -57.47% |
| Rentabilité des actifs | -48.44% |
| Marge brute | -343.01% |
| Marge opérationnelle | -2058.08% |
| Marge nette | -1941.09% |
Entreprises liées: ABOS · ALEC · CRBP · INO · MOLN · NKTX · PEPG
Explorer le secteur: Healthcare · Biotechnology
Plus de sections de FATE: Vue d'ensemble · Financiers · Valorisation · Statistiques · Estimations · Technique · Actualités · Événements
Découvrir plus: Radar — signaux d'actions sous-évaluées · Académie d'Investissement — apprenez à analyser les actions